Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes

Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes

<p>HRR gene mutations found in WGS/WES or clinical BRCA1/2 mutational testing.</p>

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Sanna Pikkusaari (15055802) (author)
Diğer Yazarlar:	Manuela Tumiati (15011915) (author), Anni Virtanen (15055805) (author), Jaana Oikkonen (14948281) (author), Yilin Li (15055808) (author), Fernando Perez-Villatoro (15055811) (author), Taru Muranen (15055814) (author), Matilda Salko (15055817) (author), Kaisa Huhtinen (15055820) (author), Anna Kanerva (15055823) (author), Heidi Koskela (15055826) (author), Johanna Tapper (15055829) (author), Riitta Koivisto-Korander (15055832) (author), Titta Joutsiniemi (15055835) (author), Ulla-Maija Haltia (15055838) (author), Heini Lassus (15055841) (author), Sampsa Hautaniemi (14948308) (author), Anniina Färkkilä (14948278) (author), Johanna Hynninen (14932815) (author), Sakari Hietanen (14932818) (author), Olli Carpén (14932812) (author), Liisa Kauppi (15055844) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Molecular and Cellular Biology Cancer Detection and Diagnosis Therapeutic Research and Development Clinical Research and Trials Biomarkers Prognostic biomarkers Chemotherapy DNA Damage and Repair Drug Resistance Clinical drug resistance Gynecological Cancers Ovarian cancer Precision Medicine
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
Yazar:: Sanna Pikkusaari (15055802)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer
Yazar:: Stephanie L. Wethington (16354020)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
Yazar:: Arun Kanakkanthara (14937731)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
Yazar:: Arun Kanakkanthara (14937731)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Yazar:: Chong Kin Liam (15331321)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Yazar:: Chong Kin Liam (15331321)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Yazar:: Chong Kin Liam (15331321)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Yazar:: Chong Kin Liam (15331321)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer
Yazar:: Jiachun Su (16990970)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table from CircIPO7 Promotes Nasopharyngeal Carcinoma Metastasis and Cisplatin Chemoresistance by Facilitating YBX1 Nuclear Localization
Yazar:: Xiaohong Hong (22681698)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Yazar:: Seung Yeon Oh (15051017)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 10 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Yazar:: Seung Yeon Oh (15051017)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Yazar:: Seung Yeon Oh (15051017)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 3 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Yazar:: Seung Yeon Oh (15051017)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Yazar:: Seung Yeon Oh (15051017)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 5 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Yazar:: Seung Yeon Oh (15051017)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 6 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Yazar:: Seung Yeon Oh (15051017)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 7 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Yazar:: Seung Yeon Oh (15051017)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 8 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Yazar:: Seung Yeon Oh (15051017)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 9 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Yazar:: Seung Yeon Oh (15051017)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Yazar:: Seung Yeon Oh (15051017)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Yazar:: Seung Yeon Oh (15051017)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
Yazar:: Kavya Ramkumar (16474203)
Baskı/Yayın Bilgisi: (2025)

Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Yazar:: Alex C.H. Liu (14961921)
Baskı/Yayın Bilgisi: (2025)

Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Yazar:: Alex C.H. Liu (14961921)
Baskı/Yayın Bilgisi: (2025)

Data file S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Yazar:: Alex C.H. Liu (14961921)
Baskı/Yayın Bilgisi: (2025)

Data file S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Yazar:: Alex C.H. Liu (14961921)
Baskı/Yayın Bilgisi: (2025)

Data file S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Yazar:: Alex C.H. Liu (14961921)
Baskı/Yayın Bilgisi: (2025)

Table S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Yazar:: Alex C.H. Liu (14961921)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma
Yazar:: Phyllis S.Y. Chong (17141520)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma
Yazar:: Phyllis S.Y. Chong (17141520)
Baskı/Yayın Bilgisi: (2025)

Figure 1 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Yazar:: Milana A. Bergamino (15038015)
Baskı/Yayın Bilgisi: (2025)

Figure 2 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Yazar:: Milana A. Bergamino (15038015)
Baskı/Yayın Bilgisi: (2025)

Figure 3 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Yazar:: Milana A. Bergamino (15038015)
Baskı/Yayın Bilgisi: (2025)

Figure 4 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Yazar:: Milana A. Bergamino (15038015)
Baskı/Yayın Bilgisi: (2025)

Figure 5 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Yazar:: Milana A. Bergamino (15038015)
Baskı/Yayın Bilgisi: (2025)

Figure 6 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Yazar:: Milana A. Bergamino (15038015)
Baskı/Yayın Bilgisi: (2025)

Movie S1 from Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics
Yazar:: Jill Gallaher (16799594)
Baskı/Yayın Bilgisi: (2025)

Movie S2 from Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics
Yazar:: Jill Gallaher (16799594)
Baskı/Yayın Bilgisi: (2025)

Movie S3 from Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics
Yazar:: Jill Gallaher (16799594)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_23u55q7ueleb5fqjfcmo2sbcie